Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.70 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.70 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.70 |
| ▸ | GGT1 | P19440 | 1/20 | 0.70 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyrocetyl SCHEMBL29508594 | 1.00 | MAPK1 (1.00) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| Dipyrocetyl SCHEMBL11121474 | 0.98 | MAPK1 (0.96) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL7430486 | 0.89 | MAPK1 (0.81) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL9336382 | 0.89 | MAPK1 (0.81) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL7172325 | 0.89 | MAPK1 (0.81) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL8667165 | 0.88 | KDM4E (0.79) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL9371172 | 0.87 | MAPK1 (0.77) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL10437865 | 0.86 | MAPK1 (0.75) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL9419449 | 0.85 | MAPK1 (0.73) | MAPK1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL12971532 | 0.85 | MAPK1 (0.73) | MAPK1KDM4EHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 935 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-11872307-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | claimed |
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | OCULAR THERAPEUTIX INC (US) | 2023-09-14 | — | — | US | claimed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | claimed |
| EP-1226821-A2 | The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome | Advanced Life Sciences, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| EP-1169294-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| EP-1169298-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | ERBB2, BTK, ERBB3 | MAPK1 204/4885KDM4E 1064/4885HSD17B10 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.